Correlation Between Novo Nordisk and Cytodyn

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Novo Nordisk and Cytodyn at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Novo Nordisk and Cytodyn into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Novo Nordisk AS and Cytodyn, you can compare the effects of market volatilities on Novo Nordisk and Cytodyn and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Novo Nordisk with a short position of Cytodyn. Check out your portfolio center. Please also check ongoing floating volatility patterns of Novo Nordisk and Cytodyn.

Diversification Opportunities for Novo Nordisk and Cytodyn

0.02
  Correlation Coefficient

Significant diversification

The 3 months correlation between Novo and Cytodyn is 0.02. Overlapping area represents the amount of risk that can be diversified away by holding Novo Nordisk AS and Cytodyn in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cytodyn and Novo Nordisk is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Novo Nordisk AS are associated (or correlated) with Cytodyn. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cytodyn has no effect on the direction of Novo Nordisk i.e., Novo Nordisk and Cytodyn go up and down completely randomly.

Pair Corralation between Novo Nordisk and Cytodyn

Considering the 90-day investment horizon Novo Nordisk AS is expected to generate 0.28 times more return on investment than Cytodyn. However, Novo Nordisk AS is 3.52 times less risky than Cytodyn. It trades about -0.01 of its potential returns per unit of risk. Cytodyn is currently generating about -0.11 per unit of risk. If you would invest  12,905  in Novo Nordisk AS on January 25, 2024 and sell it today you would lose (41.00) from holding Novo Nordisk AS or give up 0.32% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Novo Nordisk AS  vs.  Cytodyn

 Performance 
       Timeline  
Novo Nordisk AS 

Risk-Adjusted Performance

13 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Novo Nordisk AS are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of very unsteady basic indicators, Novo Nordisk displayed solid returns over the last few months and may actually be approaching a breakup point.
Cytodyn 

Risk-Adjusted Performance

2 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Cytodyn are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak fundamental indicators, Cytodyn showed solid returns over the last few months and may actually be approaching a breakup point.

Novo Nordisk and Cytodyn Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Novo Nordisk and Cytodyn

The main advantage of trading using opposite Novo Nordisk and Cytodyn positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Novo Nordisk position performs unexpectedly, Cytodyn can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cytodyn will offset losses from the drop in Cytodyn's long position.
The idea behind Novo Nordisk AS and Cytodyn pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Other Complementary Tools

Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Fundamental Analysis
View fundamental data based on most recent published financial statements
Stocks Directory
Find actively traded stocks across global markets
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years